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Abstract 
Children with major congenital anomalies often require lifelong access to health and social 
care services. Estimating future numbers of affected individuals can aid health and social care 
planning. This study aimed to estimate the number of children aged 0-15 years living with 
spina bifida or Down syndrome in England and Wales by 2020. Cases of spina bifida and 
Down syndrome born during 1998-2013 were identified from the Northern Congenital 
Abnormality Survey and the National Down Syndrome Cytogenetic Register, respectively. 
The number of infants born with spina bifida during 1998-2019 were estimated by applying 
the average prevalence rate in the North of England to actual and projected births in England 
and Wales. Poisson regression was performed to estimate the number of infants born with 
Down syndrome in England and Wales during 1998-2013 and 2004-2019. The numbers of 
children aged 0-15 living with spina bifida or Down syndrome in 2014 and in 2020 were then 
estimated by multiplying year- and age-specific survival estimates by the number of affected 
births. An estimated 956 children with isolated spina bifida, 623 children with spina bifida 
and hydrocephalus and 11,592 children with Down syndrome aged 0-15 years will be living 
in England and Wales by 2020, increases of 7.2%, 12.0% and 12.7% since 2014, 
respectively. Due to improvements in survival, an increase in population size and changes in 
maternal age distribution at delivery, we anticipate further increases in the number of children 
living with spina bifida or Down syndrome by 2020. 
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Introduction 
Spina bifida occurs in 4 per 10,000 pregnancies in Europe, with approximately 31% of these 
resulting in live births.(1)  Infant survival for children born with spina bifida has been 
reported as 71% in the UK (1985-2003) and 87% in the US (1979-1994).(2, 3) Down 
syndrome (trisomy 21) affects approximately 22 per 10,000 pregnancies in Europe, with the 
risk increasing with maternal age.(1, 4) Fifty percent of cases result in a termination of 
pregnancy or fetal death and, of the live births, infant survival is around 90%..(1, 5) The live 
birth prevalence of Down syndrome has increased because of the increased proportion of 
women entering pregnancy at advanced maternal age.(6) However, terminations of Down’s 
syndrome pregnancies due to an increase and improvements in antenatal screening have 
caused the number of live births with Down’s syndrome to remain constant(6, 7) Survival of 
affected individuals also improved over time.(3, 8, 9). While several studies worldwide have 
reported the live birth prevalence and survival of Down syndrome and spina bifida,(8, 10-14) 
to our knowledge none have combined these estimates to predict the population size of 
children with these conditions. 
Spina bifida and Down syndrome are examples of severe structural and chromosomal 
congenital anomalies respectively, where the affected individuals require lifelong specialised 
health care. This can include: complex surgeries, out-patient follow-up and access to 
disability equipment and special education, all of which come at substantial financial and 
emotional cost to society and the family.(15-17) For example,  a US study reported a 13-fold 
increase in private care expenditures for children with spina bifida compared to the general 
population.(18) Therefore, it is important to estimate the number of individuals living with 
these conditions in order to make some inferences on future costs. Given that the transition 
from pediatric to adult care occurs around age 16 in the UK, and children can require 
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additional support in adaptation to changes in the service provision, it is important to estimate 
the number of children of this age living with these conditions. 
We estimated the number of children aged 0-15 years who will be living with spina bifida or 
Down syndrome in England and Wales by the beginning of 2020. 
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Patients and Methods 
Data sources 
The Northern Congenital Abnormality Survey (NorCAS) was a population-based register that 
collected data on cases of congenital anomalies delivered to women residing in the North of 
England, covering approximately 29,000 births per year. Cases of congenital anomaly 
diagnosed before age 12 years (16 prior to 2002) were included on the NorCAS. The survey 
used multiple sources of case ascertainment, such as antenatal ultrasonography, fetal 
medicine departments, cytogenetic laboratories, the regional cardiology centre, pathology 
departments, and paediatric surgery. The register was active between 1985-2014, but was 
superseded by the National Congenital Anomaly and Rare Disease Registration Service 
(NCARDRS) in March 2015. In 2008, there was a one-off data linkage between the Office 
for National Statistics (ONS) for England death registrations and data for NorCAS cases born 
between 1985-2003. More information regarding the NorCAS and data linkage is available 
elsewhere.(2) 
The National Down Syndrome Cytogenetic Register (NDSCR) was a population-based 
register that collected data on cases of Down syndrome born to mothers resident in England 
and Wales. The register worked in collaboration with the Association of Clinical 
Cytogeneticists and their members, meaning that when a case of Down syndrome was 
diagnosed, either prenatally or postnatally, a form was completed by the corresponding 
regional cytogenetic laboratory and notified to the NDSCR. More information on the NDSCR 
can be found elsewhere.(19) For each case, data on year of birth, maternal age and place of 
residence (Wales, England: North East, North West, Yorkshire and the Humber, East, East 
Midlands, West Midlands, South East, South West, and London) was recorded (among other 
variables).  
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Live births between 1st January 1998 and 31st December 2016 by year, region and maternal 
age category were available from the ONS for England and Wales. Projected births between 
1st January 2017 and 31st December 2019, by region, year of birth and maternal age were 
available from the ONS for England (20) and by year of birth and maternal age for 
Wales.(21)  
Case classification and inclusion 
The NorCAS recorded text descriptions and WHO ICD-10 codes for up to six individual 
congenital anomalies per case (22). These were categorised into group (the organ system 
affected, e.g. ‘nervous system’), subtype (the specific condition, e.g. ‘spina bifida’), and 
syndrome (e.g. ‘Di George syndrome’) based on EUROCAT guidelines (23, 24).  Cases with 
more than one ICD code were assigned a primary diagnosis using an hierarchical approach 
described previously with the highest allocated from: 1) chromosomal syndromes; 2) genetic 
syndromes; 3) skeletal dysplasias; 4) other genetic anomalies (resulting from microdeletions 
or mutations); or 5) other syndromes of non-genetic origin (2, 23). Isolated cases were 
allocated to their primary anomaly group and subtype. Cases with two or more structural 
anomalies were reviewed to identify a primary group or subtype, or to assign a diagnosis of 
multiple anomalies (two or more unrelated structural anomalies across separate organs).  Live 
born cases of spina bifida (ICD-10: Q05) delivered between 1st January 1998 and 31st 
December 2013 in the North of England were identified from the NorCAS. Cases of spina 
bifida with chromosomal or additional structural anomalies were excluded because survival 
and temporal trends are different in these cases. However, cases with spina bifida and 
hydrocephalus were included but coded separately, because hydrocephalus occurs as a direct 
result of spina bifida and is part of the same condition.(25) 
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Data on live born cases of Down syndrome (ICD-10 Q90) delivered between 1st January 
1998-31st December 2013 in England and Wales by year, maternal age (<30, 30-34 and ≥35 
years) and region were obtained from the NDSCR. Cases of Down syndrome were only 
included if there was cytogenetic evidence that would lead to a diagnoses of Down syndrome. 
Cases of Down syndrome with multiple congenital anomalies were included as the additional 
anomalies are likely to be part of the Down syndrome. 
Statistical Analysis 
Using Poisson regression models with year of birth as the explanatory variable, we found no 
evidence of a trend over time in isolated spina bifida (p=0.17) or in spina bifida with 
hydrocephalus (p=0.54) born in the North of England between 1998-2013. Therefore, the 
number of cases of spina bifida born in England and Wales between 1998-2019 was 
estimated by multiplying the average spina bifida North of England live birth rate during 
1998-2013 by the number of actual (1998-2016) and predicted (2017-2019) live births in 
England and Wales between 2014-2019. 
Using a multivariable Poisson regression model, we found that year of birth, maternal age, 
region, and interactions between year of birth and maternal age, and year of birth and region, 
were all significantly associated with the live birth prevalence of Down syndrome (all 
p<0.001). Therefore, using the actual and predicted number of live births in England and 
Wales, the number of live births affected by Down syndrome between 2014-2019 were 
estimated from the Poisson model. In a sensitivity analysis we estimated the number of live 
births using the average Down syndrome live birth prevalence rate between 1998-2013 
applied to the number of live births between 2014-2019. Maternal age data was missing in 
11.5% of Down syndrome cases. Therefore, the proportion of cases within each maternal age 
category was multiplied by the total number of cases to provide estimated case numbers. 
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Spina bifida and Down syndrome survival according to birth year (1985-2003) was modelled 
using Royston-Parmar regression, a type of survival model that uses a flexible parametric 
approach (with cubic splines) to model baseline hazard(26), adjusted for year of birth. The 
model was extrapolated to estimate survival for children born up to 2020 at various ages e.g. 
for children born in 2004, 16 year survival (i.e. the age reached by 2020) was estimated 
specific to this year. Survival was assumed to be equal in all regions of England. These 
survival estimates were multiplied by the actual and predicted case numbers born each year 
and summed to estimate the number of children with spina bifida or Down syndrome aged 0-
15 years by 2014 and 2020. 
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Results 
Live birth prevalence 
There were 78 live born cases of spina bifida notified to the NorCAS between 1998-2013, 
including 33 (42.3%) with hydrocephalus. In the same time period, there were 509,679 live 
births in the North of England, giving a live birth prevalence of 0.9 (95% CI: 0.6-1.2) per 
10,000 live births for isolated spina bifida and 0.6 (95% CI: 0.4-0.9) for spina bifida with 
hydrocephalus. 
There were 10,985 live born cases of Down syndrome notified to the NDSCR between 1998-
2013. In the same period, there were 1,060,5934 live births in England and Wales.  The 
overall live birth prevalence of Down syndrome between 1998-2013 in England and Wales 
was 10.4 [95% CI: 10.2-10.6] per 10,000 live births, with prevalence rates of 5.2 [95% CI: 
5.0-5.4], 8.3 [95% CI: 8.0-8.6] and 27.7 [95% CI: 27.0-28.4] per 10,000 live births in 
mothers aged <30, 30-34 and ≥35 years. 
The number of actual (1998-2016) and projected live births (2017-2019) in England and 
Wales by maternal age are shown in Figure 1. The actual and predicted number of babies 
born with spina bifida or Down syndrome are shown in Figure 2. 
Survival 
There were 195 live born cases of spina bifida notified to the NorCAS between 1985-2003, 
including 90 (46.2%) with hydrocephalus. Twenty year survival was 50.0% [95% CI: 39.7-
59.5%] for spina bifida with hydrocephalus and 86.7% [95% CI: 77.7-92.2%] for isolated 
spina bifida (Figure 3A). The risk of mortality decreased by 7% per year in cases with and 
without hydrocephalus, although the trends were not statistically significant (hazard ratio 
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(HR)=0.93, 95% CI: 0.87-1.00; p=0.06 and HR=0.93, 95% CI: 0.81-1.06; p=0.27, 
respectively).  
There were 697 live born cases of Down syndrome notified to the NorCAS between 1985-
2003. Twenty year survival was 82.9% [95% CI: 79.7-85.7] (Figure 3B), with the risk of 
mortality decreasing significantly by 7% per year (HR=0.93, 95% CI 0.89-0.96; p<0.001). 
There was no significant association between (continuous) maternal age at delivery and 
mortality (HR= 0.99, 95% CI: 0.97-1.02; p=0.617). Survival estimates conditioned on year of 
delivery are shown in Tables 1 and 2. 
Survivors 
An estimated 956 and 623 children aged 0-15 years are expected to be living with isolated 
spina bifida or spina bifida with hydrocephalus by the beginning of 2020 (Table 2), of whom 
approximately 307 and 209 will be aged 0-4, 366 and 242 will be aged 5-10, 283 and 173 will 
be aged 11-15, respectively. An estimated 11,592 children aged 0-15 years are expected to be 
living with Down syndrome in 2020 (Table 2), of whom 3875 will be aged 0-4, 4321 will be 
aged 5-10 and 3396 will be aged 11-15 years old. The estimated case numbers are greater in 
2020 than in 2014, when 892 children were living with isolated spina bifida, 556 with spina 
bifida and hydrocephalus and 10,285 with Down syndrome (Table I1), estimated increases of 
7.2% (n=64), 12.0% (n=67) and 12.7% (n=1,307) , respectively. 
Sensitivity analysis 
Had we assumed the rate of Down syndrome cases born between 2014-2019 was equal to the 
average rate in England and Wales between 1998-2013, there would have been 12,100 births 
with Down syndrome during 2004-2019, of whom 11,593 may have survived until 2020. 
Compared to using the modelling methods, this was an excess of just one case. 
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Discussion 
To our knowledge, this is the only study to predict future numbers of spina bifida and Down 
syndrome in England & Wales. We predict that compared to 2014, there will be a 12.7%, 
7.2% and a 12.0% increase in the population of children aged 0-15 years living with Down 
syndrome, isolated spina bifida and spina bifida with hydrocephalus in England and Wales by 
2020, respectively.  
We used data from high quality population-based registers that are notified of cases from 
multiple sources, ensuring high case ascertainment. Survival estimates were derived from 
NorCAS data linked to ONS death registrations, where 98% of cases were traced.(2) We used 
conditional survival estimates to account for temporal changes in survival and we used age-
specific survival for more accurate estimates of the number of individuals living with the 
conditions. We examined spina bifida according to the co-occurrence of hydrocephalus, 
which is important given the difference in disease severity and therefore the different services 
and disability aids required by affected individuals. We also compared estimated case 
numbers of Down syndrome using two different methods, finding a discrepancy of only one 
case. 
We estimated survival between 2003-2019 assuming the trend in survival stayed on the same 
trajectory as between 1985-2003. Therefore, our survival estimates do not account for any 
changes in services or events that may have set the trend in survival on a different trajectory. 
Similarly, we assumed that the live birth prevalence of spina bifida between 2014-2019 
would be the same as the average prevalence between 2000-2013. Our trends therefore do not 
account for any improvements in  prenatal diagnosis rates or changes in the prevalence of 
spina bifida risk factors, such as maternal obesity(27) A similar assumption was made for the 
estimation of the live birth prevalence of Down syndrome between 2014-2019. Therefore, the 
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numbers we have projected do not account for the introduction of non-invasive prenatal 
diagnosis (NIPD), which may increase the number of women opting for screening and 
therefore the rate of terminations for fetal anomaly and decrease the number of live births. 
However, NIPD is currently only available in the private setting,with an evaluative roll out in 
the NHS planned for late 2018 or 2019(28), so we would not expect this to have greatly 
impacted our estimations. Our estimates may be a useful comparison when evaluating the 
impact of NIPD in the UK in the future. Our estimated case numbers took into account 
changes in the birth population, using ONS population projections which are based on a 
variety of variables including fertility, mortality and migration. While our estimates of 
survival for spina bifida without hydrocephalus are comparable to a previous study in a 
similar era (1979-1994), our estimates for spina bifida with hydrocephalus are lower.(3) This 
is perhaps related to different case mixes due to differences in termination rates or uptake of 
folic acid between the populations.  
We assumed that the prevalence of spina bifida was the same in England and Wales as it was 
in the North of England. However, the North of England has greater smoking rates than other 
regions of England and Wales.(29) A recent systematic review showed that smoking during 
pregnancy increases the odds of spina bifida by 55%, meaning the North of England may 
have a slightly increased prevalence of spina bifida.(30) Compared to the rest of England and 
Wales, the North of England has a lower proportion of residents from ethnic minority 
groups.(31) This may have resulted in an increase in the prevalence of spina bifida in the 
North of England given that several US studies have reported a decreased risk of spina bifida 
in non-Hispanic Blacks compared to Whites.(32, 33) Similarly, a systematic review showed 
that compared to Caucasian women, South Asian and African women in the UK had lower 
preconception use of folic acid, which reduces the risk of neural tube defects.(34) The North 
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of England also has high levels of socioeconomic deprivation and a lower proportion of older 
mothers, which may have conversely inflated the prevalence of spina bifida.(35, 36)   
We were only able to model maternal age categorically, which does not entirely capture the 
association with maternal age. For example, the categorisation of maternal age ≥35 does not 
account for the rising maternal age within this group, i.e. over time the fertility rate has been 
rising in mothers aged 40 and above.(36) This may explain why we identified an increasing 
trend in Down syndrome prevalence in mothers aged ≥35. Additionally, 11% of the Down 
syndrome cases had missing maternal age data. We assumed that this data was missing at 
random and therefore inflated the number of cases within each maternal age category. If the 
data was not missing at random (i.e. if the missingness occurred more for one maternal age 
category than for another), then this approach may mean our trends over time are slightly 
inaccurate. Given only 11% of cases had missing maternal age however, this is not likely to 
have had a great impact on the projections. 
A previous study estimated the number of individuals living with Down syndrome in England 
and Wales by 2011 was 37,090, with 10,438 of these being aged ≤18.(37) For 2014, we 
estimated that there would have been 10,285 children aged 0-15 years, which suggests we 
estimated a higher number of individuals than the previous study. This was likely due to our 
different estimates of first year survival, which were greater in our study than in Wu et al’s, 
which estimated survival by pooling rates from previous publications. 
We estimate that the population of children aged 0-15 with spina bifida or Down syndrome 
will increase slightly from 2014. This increase is mainly due to the increasing number of 
births in the population with the increase in cases of Down syndrome being associated with 
the increasing number of births to mothers aged over 35. A likely increase of older mothers in 
the ≥35 group may have contributed to a further increase in the prevalence of Down 
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syndrome. The small yearly increases in survival also contributed to the increase in the 
number of children living with spina bifida and Down syndrome between 2014-2020. This 
increase is likely going to be observed in other populations, including the United States. 
Therefore, this estimation of future cases is important for planning specialised health and care 
services, including the associated costs. This is important given that children with spina 
bifida or Down syndrome have a 13-fold increase in private care expenditures compared to 
the general population of the US.(18, 38) Therefore, it is important to estimate the number of 
individuals living with these conditions in order to make some inferences on future costs. 
This is of particular importance given the changes in funding currently proposed in the UK 
and US health sectors. 
Conclusions 
Children with spina bifida and Down syndrome often have lifelong specialised health and 
social care needs. Our estimated increase in the numbers of affected individuals can aid 
healthcare planning and cost estimation to ensure these services are in place, which is 
particularly important given current austerity in the UK. 
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Figure legends 
Figure 1 Actual and predicted population live births in England and Wales by maternal age 
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Figure 2 Actual and predicted number of births affected by A) spina bifida or B) Down 
syndrome in England & Wales 
Figure 3 Kaplan-Meier survival estimates for cases born 1985-2003 in the North of England 
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Table 1 Estimated births and survivors with isolated spina bifida, spina bifida with hydrocephalus and Down syndrome in England & Wales, 1998-2013 
Year of 
birth 
Survival 
age 
Isolated spina bifida Spina bifida with hydrocephalus Down syndrome 
Conditional 
Survival 
estimate* 
Cases 
born‡ 
Cases 
surviving 
to 2014 
Conditional 
Survival 
estimate* 
Cases 
born‡ 
Cases 
surviving to 
2014 
Conditional 
Survival 
estimate* 
Cases 
born† 
Cases 
surviving to 
2014 
1998 16 92.0 56 52 70.0 41 29 88.5 631 558 
1999 15 92.6 55 51 71.7 40 29 89.3 602 538 
2000 14 93.1 53 50 73.4 39 29 90.1 591 533 
2001 13 93.6 52 49 75.0 38 29 90.9 576 524 
2002 12 94.1 53 49 76.5 39 30 91.6 585 536 
2003 11 94.5 55 52 78.0 40 31 92.3 613 565 
2004 10 94.9 56 54 79.4 41 33 92.9 661 614 
2005 9 95.2 57 54 80.7 42 34 93.3 741 692 
2006 8 95.6 59 56 81.9 43 35 94.0 758 712 
2007 7 95.9 61 58 83.1 45 37 94.5 718 679 
2008 6 96.2 63 60 84.2 46 39 95.0 750 712 
2009 5 96.5 62 60 85.3 46 39 95.4 788 752 
2010 4 96.8 64 62 86.4 47 40 95.9 731 701 
2011 3 97.0 64 62 87.4 47 41 96.3 752 724 
2012 2 97.2 64 63 88.5 47 42 96.8 772 747 
2013 1 97.5 62 60 89.8 45 41 97.4 716 698 
TOTAL -  937 892  686 556  10,985 10,285 
*Modelled survival conditional on year of birth and survival age, modelled using cases born 1985-2003 to mothers resident in the North of England  
† Actual cases 
‡Estimated cases based on average prevalence in the North of England 
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Table 2 Estimated births and survivors with isolated spina bifida, spina bifida with hydrocephalus and Down syndrome in England & Wales, 2004-2019 
Year of 
birth 
Survival 
age 
Isolated spina bifida Spina bifida with hydrocephalus Down syndrome 
Conditional 
Survival 
estimate* 
Cases 
born† 
Cases 
surviving 
to 2020 
Conditional 
Survival 
estimate* 
Cases 
born† 
Cases 
surviving to 
2020 
Conditional 
Survival 
estimate* 
Cases 
born‡ 
Cases 
surviving to 
2020 
2004 16 94.8 56 54 79.1 41 32 92.5 661 611 
2005 15 95.2 57 54 80.4 42 33 93.1 741 690 
2006 14 95.5 59 56 81.7 43 34 93.6 758 710 
2007 13 95.9 61 58 82.8 45 36 94.1 718 676 
2008 12 96.2 63 60 83.9 46 37 94.6 750 709 
2009 11 96.4 62 60 85.0 46 39 95.0 788 749 
2010 10 96.7 64 62 86.0 47 39 95.4 731 697 
2011 9 96.9 64 62 86.9 47 41 95.8 752 720 
2012 8 97.2 64 63 87.8 47 41 96.1 772 742 
2013 7 97.4 62 60 88.6 45 42 96.5 716 691 
2014 6 97.6 61 60 89.4 45 40 96.8 746 722 
2015 5 97.7 62 60 90.1 47 41 97.1 763 741 
2016 4 97.9 61 60 90.9 47 41 97.3 779 759 
2017 3 98.1 63 62 91.6 47 41 98.0 791 773 
2018 2 98.2 63 62 92.3 47 42 98.0 809 793 
2019 1 98.4 64 63 93.2 47 43 98.4 824 810 
TOTAL - - 987 956 - 730 623 - 12,100 11,592 
*Modelled survival conditional on year of birth and survival age, modelled using cases born 1985-2003 to mothers resident in the North of England  
† Predicted cases 
‡Actual cases 2004-2013, predicted cases 2014-2019 
 
Please note, surviving cases may not exactly sum to the total due to rounding error
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